The Indian Pharmacopoeia Commission (IPC) has been inducted as a member of the Pharmacopoeial Discussion Group (PDG), as announced during the PDG’s annual meeting held on October 3-4, 2023, in Hyderabad, India. IPC's membership reflects its significant role and contribution to the global pharmaceutical landscape.

About the PDG

PDG, a prestigious international consortium, was established by the European Pharmacopoeia (Ph. Eur.), Japanese Pharmacopoeia (JP), and the U.S. Pharmacopoeia (USP). The World Health Organization (WHO) also engages with the PDG as an observer, enhancing the collaboration and exchange of knowledge among these pivotal organizations.

PDG is renowned for its efforts in harmonizing pharmacopoeial standards worldwide. These standards are instrumental in assuring the quality of medicines at every stage of the manufacturing process. By establishing uniform criteria for testing identity, purity, potency, and performance, PDG aids manufacturers and regulatory bodies in ensuring that the pharmaceuticals meet international quality benchmarks.

PDG’s harmonization efforts are pivotal in reducing the analytical and procedural burdens on manufacturers. It ensures that pharmacopoeial requirements are consistent across various geographical locations. This harmonization is essential for maintaining a universal scientific benchmark in medicines quality, underlining the shared objective of safeguarding public health on a global scale.

For more details, please see the EDQM press release here.